Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SGN-516 by SGN Nanopharma for Diabetic Neuropathy: Likelihood of Approval
SGN-516 is under clinical development by SGN Nanopharma and currently in Phase I for Diabetic Neuropathy. According to GlobalData, Phase...